Lactobacillus gasseri BNR17,
does it really help with Reduced visceral fat area and waist circumference within 12 weeks in adults with obesity?
research showsBNR17 is rated C. In a 90-person, 12-week randomized double-blind trial, high-dose BNR17 reduced computed-tomography visceral adipose area by 21.6 cm2 versus placebo. Waist circumference, however, fell significantly only from baseline within each BNR17 group, without a demonstrated between-group difference. An earlier 62-person trial found no significant between-group differences in weight, waist circumference, or visceral fat. Positive evidence is concentrated in product-linked studies of this proprietary strain, and computed-tomography area and waist circumference are surrogate rather than clinical outcomes, so rules ① and ②-b cap the grade at C. The result cannot establish durable weight loss, reduced diabetes or cardiovascular events, or effects of other strains or products.
ads claimMarketing can expand breast-milk-derived probiotic and visceral-fat reduction into major weight loss, treatment of abdominal obesity, or prevention of metabolic disease. The strongest defensible claim is a modest computed-tomography area change in one small 12-week trial of a specific high-dose BNR17 product.
Useful facts when choosing a product
- The evidence concerns the named BNR17 strain rather than Lactobacillus gasseri as a species, so it cannot be transferred to products with different strain identifiers, viable counts, or storage conditions.
- The 2018 trial used 10^9 or 10^10 CFU per day for 12 weeks, and the positive placebo-adjusted visceral-fat result occurred in the 10^10-CFU high-dose group.
- Probiotics are generally tolerated but can cause gas, bloating, abdominal discomfort, or altered bowel habits. Severe immunocompromise, a central venous catheter, or critical illness warrants clinical advice because rare bloodstream infection can occur.
- Product-specific functional-food recognition is not equivalent to approval as an obesity medicine and does not guarantee substantial weight loss or equivalence across marketed products.
What the research actually shows
Jung 2013 randomized 62 adults with body mass index at least 23 kg/m2 and fasting glucose at least 100 mg/dL and analyzed 57. Weight fell 1.1 kg and waist circumference 2 cm within the BNR17 group, but neither differed significantly from placebo, and computed-tomography visceral and subcutaneous fat did not change. Kim 2018 randomized 90 adults with body mass index 25 to 35 to placebo, 10^9 CFU per day, or 10^10 CFU per day. High-dose BNR17 reduced computed-tomography visceral fat area by 21.6 cm2 versus placebo, but weight, body mass index, several body-composition measures, and biochemical measures did not differ between groups; waist was significant only within groups. No trial of durable weight maintenance, incident diabetes, or cardiovascular events was found.
Why this is classified as C (42)
The high-dose computed-tomography visceral-fat endpoint was positive in a 90-person trial, but it is a surrogate, waist circumference lacked a demonstrated between-group effect, and an earlier 62-person trial was negative versus placebo for weight, circumferences, and computed-tomography fat. Concentration of positive evidence in proprietary-strain, product-linked research invokes the rule ① and ②-b ceiling, giving C with 42 points. Gastrointestinal effects and infection risk in vulnerable patients are separate safety issues.
Counterpoint. A specific product may be tried alongside lifestyle treatment, but objective weight and waist trends should be checked after 12 weeks and continued expense is poorly supported if nothing changes. Diet, activity, sleep, behavioral care, and indicated medical obesity treatment remain central.
Rejudgment record. Cross-check revision — Accepted the placebo-adjusted high-dose computed-tomography visceral-fat reduction, but applied rules ① and ②-b because waist circumference was a within-group change, the earlier trial was negative between groups, endpoints were surrogate, and positive evidence was concentrated in proprietary-strain product-linked research
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced computed-tomography visceral fat area over 12 weeks in adults with obesity | C | The high-dose arm was positive in a 90-person trial, but evidence is small, surrogate, product-linked, and not reproduced earlier. |
| Reduced waist circumference over 12 weeks in adults with obesity | C | The 2018 trial showed within-group reductions from baseline but did not demonstrate a placebo-adjusted effect. |
| Clinically meaningful weight loss in adults with obesity | D | Neither human trial demonstrated a significant placebo-adjusted reduction in body weight. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kim J et al. 2018 | Twelve-week randomized double-blind placebo-controlled three-arm trial | 90 | Support linked to the Korea Food Research Institute and BNR17-associated industry, with Biofood CRO authors | Computed-tomography abdominal fat area, weight, body mass index, waist, body composition, and biochemical measures | High-dose visceral fat differed from placebo by -21.6 cm2, P=.012; waist fell only within groups and biochemical measures did not differ between groups. | Key small positive surrogate-endpoint trial |
| Jung SP et al. 2013 | Twelve-week randomized double-blind placebo-controlled trial | 57 | Supported by Solomon CRO and funded by Bioneer, with Bioneer R&D authors | Weight, body mass index, waist and hip circumferences, computed-tomography abdominal fat, and metabolic measures | Weight and waist changed within the BNR17 group but not significantly versus placebo, and visceral and subcutaneous fat did not change. | Earlier negative trial limiting replication |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Lactobacillus gasseri BNR17 x reduced visceral fat area and waist circumference over 12 weeks — Evidence Grade C·42. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/lactobacillus-gasseri-bnr17-visceral-fat-waist-obesity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.